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Interstitial lung disease: raising the index of suspicion
in primary care
Joseph D Zibrak1 and David Price2
Interstitial lung disease (ILD) describes a group of diseases that cause progressive scarring of the lung tissue through inﬂammation
and ﬁbrosis. The most common form of ILD is idiopathic pulmonary ﬁbrosis, which has a poor prognosis. ILD is rare and mainly a
disease of the middle-aged and elderly. The symptoms of ILD—chronic dyspnoea and cough—are easily confused with the
symptoms of more common diseases, particularly chronic obstructive pulmonary disease and heart failure. ILD is infrequently seen
in primary care and a precise diagnosis of these disorders can be challenging for physicians who rarely encounter them. Conﬁrming
a diagnosis of ILD requires specialist expertise and review of a high-resolution computed tomography scan (HRCT). Primary
care physicians (PCPs) play a key role in facilitating the diagnosis of ILD by referring patients with concerning symptoms to a
pulmonologist and, in some cases, by ordering HRCTs. In our article, we highlight the importance of prompt diagnosis of ILD and
describe the circumstances in which a PCP’s suspicion for ILD should be raised in a patient presenting with chronic dyspnoea on
exertion, once more common causes of dyspnoea have been investigated and excluded.
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INTRODUCTION
Interstitial lung disease (ILD) is an umbrella term, synonymous
with diffuse parenchymal lung disease, for a large group of lung
diseases affecting the tissue and space around the air sacs of the
lungs, which cause progressive scarring of lung tissue through
inﬂammation and ﬁbrosis.1 ILD is uncommon compared to other
pulmonary problems seen in general practice. The prevalence of
ILD has been estimated as 81/100,000 in males and 67/100,000 in
females.2
Primary care physicians (PCPs) often misdiagnose ILD as chronic
obstructive pulmonary disease (COPD), bronchitis, emphysema,
asthma, heart disease or other common diseases with similar
symptoms.3 In a US survey of 1,583 patients, 54.6% reported a
delay of ⩾ 1 year between the onset of breathing problems and
receiving a diagnosis of pulmonary ﬁbrosis.3
A diagnosis of ILD should be conﬁrmed by a pulmonologist
working with a radiologist experienced in the differential
diagnosis of ILD, but PCPs have a crucial role to play in recognising
the need for further evaluation. This paper describes the
circumstances in which a PCP’s suspicion for ILD should be raised
in a patient with chronic dyspnoea and the importance of
referring patients who may have ILD promptly to a pulmonologist
to conﬁrm the diagnosis.
WHAT IS ILD?
The American Thoracic Society and European Respiratory Society
deﬁne ILD as a heterogeneous group of non-neoplastic disorders
resulting from damage to the lung parenchyma by inﬂammation
and ﬁbrosis that diminish the lung’s capacity for alveolar gas
diffusion.1 The latest classiﬁcation of ILDs is shown in Figure 1.1,4
Most ILDs are ‘restrictive’ pulmonary disorders, i.e., the lungs have
a reduced ability to expand on inhalation. This is in contrast to
‘obstructive’ pulmonary disorders such as asthma, COPD and
emphysema, in which the airways of the lungs become narrowed
or blocked so the patient cannot exhale completely. Some forms
of ILD are associated with environmental or occupational
exposures (e.g., asbestosis or silicosis), the use of certain drugs5
or with connective tissue disorders.2,6,7 Others, including the
idiopathic interstitial pneumonias, have no known cause.1 Some
cases of ILD do not meet the speciﬁc deﬁnitions for any form of
ILD and are considered ‘unclassiﬁable’. This may be the case when
there are non-speciﬁc or conﬂicting clinical, radiological or
histopathological ﬁndings, or when patients are unable or
unwilling to undergo diagnostic procedures.8
Idiopathic pulmonary ﬁbrosis (IPF) is the most common
idiopathic interstitial pneumonia.1 IPF also has the worst
prognosis; the 5-year survival rate (20–40%)9 is lower than many
common cancers.10 While most cases of IPF are sporadic, familial
forms of the disease may account for ~ 5–20% of cases.11,12
The prevalence of IPF in the US has been estimated as 14.0–27.9
cases/100,000 using narrow case deﬁnitions and as 42.7–63
cases/100,000 using broad case deﬁnitions.13 In Europe, the
estimated prevalence of IPF was 1.25–23.4 cases/100,000.13 The
incidence of IPF increased with age and was higher in men than in
women (10.7 vs. 7.4 per 100,000 patient-years in the US).13
RECOGNISING ILD
As highlighted in the international guidelines for the diagnosis of
ILD, a diagnosis of ILD should be made by review of clinical,
pulmonary, radiological and possibly histopathological features.4
However, PCPs have a key role to play in identifying patients who
may have ILD and referring them to a pulmonologist or an ILD
clinic with a multidisciplinary team. PCPs can also help detect
non-idiopathic forms of ILD by reviewing relevant occupational,
environmental and drug exposures, as well as by assessing the
presence of extrapulmonary symptoms suggestive of connective
tissue disease.
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One of the challenges for PCPs in determining whether a
patient may have ILD is the lack of speciﬁcity of its symptoms.
Breathlessness and cough are seen in many diseases that
commonly occur in middle-aged and elderly patients, most
notably COPD and heart failure. Once non-respiratory causes of
breathlessness have been excluded, PCPs should consider the
possibility of ILD in all middle-aged or elderly patients who
present with unexplained chronic dyspnoea on exertion, particu-
larly those who are more breathless than would be expected
based on their lung function and other contributory factors such
as obesity, or who have a cough of more than several months’
duration. The suspicion of ILD should be raised in patients with a
presumptive obstructive lung disease or congestive heart failure
who fail to beneﬁt from regular therapy, and in patients with a
non-speciﬁc chest X-ray.
A diagnosis of asthma or COPD should be conﬁrmed using the
appropriate diagnostic criteria. If diagnostic criteria are not met,
further assessments should be performed to ensure that the
correct diagnosis is made and patients are not given inappropriate
therapies. A diagnosis of COPD should be conﬁrmed by
spirometry. Obstructive lung disease is characterised by a
disproportionate reduction of maximal airﬂow from the lung in
relation to the maximal volume that can be displaced from the
lung (forced vital capacity (FVC)), deﬁned by a signiﬁcantly
reduced forced expiratory volume in 1s (FEV1)/FVC ratio.
14
Spirometry may be normal in the early phases of ILD, and
patients with both pulmonary ﬁbrosis and emphysema often have
lung volumes within normal limits.15 However, restrictive lung
disease tends to be characterised by a reduction in total lung
capacity and a normal or elevated FEV1/vital capacity ratio.
16
Patients with ILD tend to show a reduced FVC, which declines as
the disease progresses,17 and many experience oxygen desatura-
tion with only minimal exertion. PCPs often order chest radio-
graphs in patients with chronic respiratory symptoms. As patients
with COPD have largely normal chest radiographs, the presence of
even subtle abnormalities such as increased interstitial markings
or nodular opacities warrants further investigation. Patients
presenting with a history of ⩾ 6 months’ breathlessness on
exertion with no evidence of obstruction should be assessed for
conditions that may cause breathlessness, such as chronic heart
failure, asthma, COPD, bronchiectasis, pleural effusion, abdominal
splinting and anaemia.18 If these conditions are not present,
patients should not only have spirometry and diffusing capacity
for carbon monoxide measured, but also be referred for a high-
resolution computed tomography scan. High-resolution com-
puted tomography scans are vital for the diagnosis of ILD and
allow for differentiation among the types of ILD.19
PCPs should take a comprehensive medical history in all
patients presenting with chronic dyspnoea, including questions
about their employment history, as some forms of ILD such as
asbestosis and silicosis are linked to environmental factors,1 and
individuals who have worked with livestock or birds, or been
subjected to high exposure to dust or fumes, may have a higher
risk of IPF.20 A medical history may reveal the use of medications
that may cause drug-induced ILD (DILD), such as chemother-
apeutic agents (e.g., cyclophosphamide, carmustine, busulphan),
antibacterial agents (e.g., sulphonamide, nitrofurantoin) or cardio-
vascular agents (e.g., amiodarone).5 The likelihood of developing
DILD is idiosyncratic and largely unpredictable and the underlying
mechanisms are not fully understood.5 PCPs should also assess for
extrapulmonary symptoms, such as fatigue, joint pain and
stiffness, which may suggest connective tissue disease.20
An early clinical test that can aid diagnosis of ILD is lung
auscultation. Patients with many types of ILD commonly present
with inspiratory ‘crackles’. These crackles, which are discontinuous,
short sounds similar to those heard when slowly separating Velcro,
are heard even in the early stages of ILD when the patient takes
slow, deep breaths.21 Unlike the crackles occasionally heard in
healthy elderly subjects, which disappear after several deep
breaths, these ﬁne crackles are heard consistently at end
inspiration and originate from the basal areas of the lung,
progressing to the upper zones as disease becomes more
severe.21 Although higher in frequency,21 crackles associated with
ILD may be confused with the crackles heard in patients with heart
failure. Finger clubbing, where reduced oxygenation of the blood
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Figure 1. Classiﬁcation of ILDs.4
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causes the ﬁngertips and ﬁngernails to spread out and become
rounder, is seen in 25–50% of patients with IPF.22
The differential features of ILD and COPD are shown in Table 1.
IMPORTANCE OF PROMPT DIAGNOSIS OF ILD
Patients with ILD who are misdiagnosed may receive inappropri-
ate and ineffective treatment. Such treatment may be harmful
physically (e.g., patients may experience adverse effects of
medication without gaining any beneﬁt) or psychologically (e.g.,
it is disheartening for patients to be given several treatments that
do not work). There are few recommended treatments for ILD,
although corticosteroids appear to be effective in the treatment of
cryptogenic organising pneumonia and desquamative interstitial
pneumonia.23 The latest international guidelines for the manage-
ment of IPF, issued in 2011, did not recommend any speciﬁc
pharmacological treatments for the chronic treatment of IPF, but
long-term oxygen therapy was strongly recommended for
patients with clinically signiﬁcant resting hypoxaemia and a weak
recommendation was made for pulmonary rehabilitation in the
majority of patients.12
The anti-ﬁbrotic agent pirfenidone has been approved for the
treatment of IPF in Japan, India, China and Canada and for the
treatment of mild to moderate IPF in Europe, but has not been
approved in the US. An additional Phase III trial of pirfenidone has
recently reported results and showed that pirfenidone reduced
the decline in FVC percent predicted.24 There are several other
agents in clinical development for the treatment of IPF, the most
advanced of which is the tyrosine kinase inhibitor nintedanib, for
which the results of two Phase III INPULSIS trials have recently
been announced.25 In both the INPULSIS trials, nintedanib
signiﬁcantly reduced the decline in FVC over the 52-week
treatment period, consistent with a slowing of disease progres-
sion. In contrast, warfarin and triple therapy with prednisone,
azathioprine and N-acetylcysteine have been shown to be harmful
for patients with IPF,26,27 highlighting the importance of potential
therapies being evaluated in controlled trials before they are used
in clinical practice. Acetylcysteine alone appears not to be harmful,
but to have no efﬁcacy as a treatment for IPF.28
PCPs treating patients with ILD should address comorbidities
such as gastroesophageal reﬂux disease , pulmonary hypertension
(PH) and emphysema. The prevalence of gastroesophageal reﬂux
disease in patients with ILD29 and IPF30 is very high and there is
some evidence that the use of gastroesophageal reﬂux disease
treatments in patients with IPF is a predictor of longer survival
time.31 PH is also common in patients with ILD.32 In patients with
IPF, PH has a reported incidence of 32–84% and is associated with
decreased exercise capacity and worse prognosis.33 Patients with
IPF, emphysema and PH have a particularly dismal prognosis.15
Patients with IPF may also have an increased risk of acute coronary
syndrome and deep vein thrombosis.34
The clinical course and prognosis of the different types of ILD
are highly variable.1 Even if pharmacological treatment is not
appropriate, it is important that a patient receives the correct
diagnosis so that their physician can provide appropriate
information and support. Data from a US-based survey of 1,448
patients with IPF or caregivers of patients with IPF highlight that
there is a need for improved patient education regarding
diagnosis and management.3 Less than half of the respondents
felt well informed about treatment options, and the role of
pulmonary rehabilitation, supplemental oxygen and lung
transplantation.3 Receiving a diagnosis with such a poor prognosis
may be difﬁcult for the patient, and they may need time to start to
come to terms with the diagnosis before they can fully
comprehend the information they receive. Patients may also
beneﬁt from contacting patient organisations for advice and
support.
The majority of patients with ILD should have the opportunity
for referral to a pulmonary rehabilitation programme.
Comprehensive programmes involve not only exercise training
with aerobic conditioning, strength and endurance training and
respiratory therapy, but also behaviour modiﬁcation techniques.35
In a large cohort of 402 patients with IPF, pulmonary rehabilitation
had a positive effect on patients’ pulmonary function and quality
of life.36
At present, lung transplant is the only therapy that has been
shown to improve survival in patients with IPF, but it is available
only to selected patients.22 The eligibility criteria for lung
transplantation vary between and even within countries, but
international guidelines stress that the early referral of patients
with IPF for transplantation should be promoted.37 Prompt
diagnosis of IPF also makes it more likely that a patient will meet
the criteria for participation in a clinical trial; most clinical trials in
IPF are restricted to patients with mild or moderate impairment of
lung function.
CONCLUSIONS
ILD presents with symptoms similar to other chronic respiratory
conditions and is frequently misdiagnosed in primary care, most
commonly as COPD and heart failure. Prompt diagnosis of ILD is
important to ensure that patients receive appropriate care and
support, and to enable them to be considered for lung
transplantation or clinical trials. PCPs have a key role to play in
expediting the diagnosis of ILD by referring middle-aged/elderly
patients with unexplained chronic dyspnoea and cough who do
not meet the diagnostic criteria for other diseases to an ILD centre
or pulmonologist with expertise in this group of disorders.
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Table 1. Differential features of ILD and COPD
ILD COPD
Physical examination
Inspiratory crackles21 ✓ ×
Wheezing14 × ✓
Finger clubbing 22 ✓ ×
Spirometry16
Reduction in TLC ✓ ×
Reduced FEV1/FVC ratio × ✓
Response to
bronchodilators
× ✓
Chest radiographs1 Show speciﬁc patterns of
abnormality
Largely
normal
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in 1s; FVC, forced vital capacity; ILD, interstitial lung
disease.
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